Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice
Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice
复制标题
DOI：
10.1002/jmv.10279
复制
发表时间：
2003-02-01
影响因子：
12.7
通讯作者：
Baba, M
中科院分区：
文献类型：
--
作者：
Akagi, T;Kawamura, M;Baba, M
粘液分泌型伊加被认为在预防人类免疫缺陷病毒1型（HIV-1）通过性交传播中具有重要作用。因此，在生殖道中诱导HIV-1特异性伊加抗体的物质可能成为预防HIV-1感染的疫苗的有希望的候选者。我们以前曾报道，刀豆球蛋白A固定的聚苯乙烯纳米球（Con A-NS）可以有效地捕获HIV-1颗粒和gp 120抗原在其表面上，并与灭活的HIV-1捕获纳米球（HIV-NS）阴道内免疫诱导小鼠阴道抗HIV-1伊加抗体。在这项研究中，各种策略的免疫与HIV-NS进行诱导HIV-1特异性伊加反应在小鼠生殖道。通过阴道内、经口、鼻内或腹腔内给药HIV-NS。孕激素治疗增强抗HIV-1伊加免疫阴道内显着，但鼻内免疫与HIV-NS更有效的阴道伊加反应相比，其他免疫途径。此外，鼻内免疫小鼠的阴道洗液能够中和HIV-1（IIIB）。因此，应用HIV-NS是一种通过小鼠阴道粘膜促进HIV-1特异性伊加应答的实用方法，鼻内似乎是该动物模型中有效的免疫途径。鼻内免疫HIV-NS应进一步追求其作为HIV-1预防性疫苗的潜力。
Mucosal secretory IgA is considered to have an important role in the prevention of human immunodeficiency virus type 1 (HIV-1) transmission through sexual intercourse. Therefore, substances that induce HIV-1-specific IgA antibody in the genital tract may become promising candidates for prophylactic vaccine against HIV-1 infection. We have previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and gp120 antigens on their surface and that intravaginal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody in mice. In this study, various strategies for immunization with HIV-NS were undertaken to induce HIV-1-specific IgA response in the mouse genital tract. HIV-NS were administered intravaginally, orally, intranasally or intraperitoneally to mice. Progesterone treatment enhanced the anti-HIV-1 IgA response to intravaginal immunization significantly, but intranasal immunization with HIV-NS was more effective compared with other immunization routes in terms of vaginal IgA response. In addition, vaginal washes from intranasally immunized mice were capable of neutralizing HIV-1(IIIB). Thus, application of HIV-NS is a practical approach to promote HIV-1-specific IgA response by the vaginal mucosa in the mouse and intranasal appears to be an effective immunization route in this animal model. Intranasal immunization with HIV-NS should be further pursued for its potential as an HIV-1 prophylactic vaccine.